EDAP Schedules Webcast and Conference Call for Fourth Quarter and Full Year
LYON, France, March 12, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP),
the global leader in therapeutic ultrasound, announced today details relating
to its fourth quarter and full year 2012 results announcement, which will take
place on Tuesday, April 2, 2013, before the opening of the market.
EDAP will hold a conference call on Tuesday, April 2, 2013 at 8:30 a.m. EDT to
discuss the results. The dial-in numbers are (877) 317-6789 for domestic
callers and (412) 317-6789 for international. The conference ID number for
both is 10026204. A live Webcast of the conference call will be available
online from the investor relations page of the Company's corporate Website at
After the live Webcast, the call will remain available on EDAP's Website,
www.edap-tms.com, through May 2, 2013. In addition, a telephonic replay of the
call will be available until April 12, 2013. The replay dial-in numbers are
(877) 344-7529 for domestic callers and (412) 317-0088 for international
callers. Please use event passcode: 10026204.
About EDAP TMS SA
EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically
proven choice for high-intensity focused ultrasound (HIFU) treatment of
localized prostate cancer. HIFU treatment is shown to be a minimally invasive
and effective treatment option with a low occurrence of side effects.
Ablatherm-HIFU is generally recommended for patients with localized prostate
cancer (stages T1-T2) who are not candidates for surgery or who prefer an
alternative option, or for patients who failed radiotherapy treatment.
Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High
Intensity Focused Ultrasound) is currently undergoing evaluation in a
multicenter U.S. Phase II/III clinical trial under an Investigational Device
Exemption granted by the FDA, the ENLIGHT U.S. clinical study. The Company
also is developing this technology for the potential treatment of certain
other types of tumors. EDAP TMS SA also produces and commercializes medical
equipment for treatment of urinary tract stones using extra-corporeal
shockwave lithotripsy (ESWL). For more information on the Company, please
visit http://www.edap-tms.comand http://www.hifu-planet.com.
In addition to historical information, this press release contains
forward-looking statements that involve risks and uncertainties. These include
statements regarding the Company's growth and expansion plans, the
conclusiveness of the results of and success of its Ablatherm-HIFU clinical
trials and expectations regarding the IDE submission to and approval by the
FDA of the Ablatherm-HIFU device. Such statements are based on management's
current expectations and are subject to a number of uncertainties, including
the uncertainties of the regulatory process, and risks that could cause actual
results to differ materially from those described in these forward-looking
statements. Factors that may cause such a difference include, but are not
limited to, those described in the Company's filings with the Securities and
Exchange Commission and in particular, in the sections "Cautionary Statement
on Forward-Looking Information" and "Risk Factors" in the Company's Annual
Report on Form 20-F. Ablatherm-HIFU treatment is in clinical trials, but not
FDA-approved or marketed in the United States.
CONTACT: Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 72
The Ruth Group
Press spacebar to pause and continue. Press esc to stop.